Today: 9 June 2026
Planet Labs Earnings Beat as Record Revenue Brings Nvidia AI Push Into Focus

Planet Labs Earnings Beat as Record Revenue Brings Nvidia AI Push Into Focus

SAN FRANCISCO, March 19, 2026, 2:19 PM PDT

Planet Labs turned in record revenue for both the quarter and the year on Thursday, as the Earth-imaging company pointed to another strong stretch ahead while leaning further into AI and satellite offerings. Revenue jumped 41% in the fourth quarter to $86.8 million. For the full year, sales were up 26% at $307.7 million.

This quarter’s numbers actually grabbed attention—analysts were braced for roughly 27.5% revenue growth, and they hadn’t budged on those estimates lately. After a streak of missed revenue marks over the past couple years, the company managed to beat that backdrop with a result that looked much cleaner than expected.

The timing coincides with geospatial intelligence — satellite data tracking shifts on the ground — taking on a sharper role in conflict zones. Last week, Reuters reported that Planet pushed out access to Middle East imagery by 14 days, aiming to keep adversaries from turning it on U.S. and allied forces. Defense consultant Chris Moore notes that AI is cracking open geospatial analysis, a field mainly walled off for military experts until now.

Planet reported a 106% surge in remaining performance obligations, bringing contracted but not yet recognized revenue to $852.4 million. Backlog, which captures a wider scope by counting some work that could still be canceled, climbed 79% to $900.4 million. Cash, cash equivalents and short-term investments totaled $640.1 million at year’s end.

Planet wrapped up its first full fiscal year turning a profit on both adjusted EBITDA and free cash flow, according to president and CFO Ashley Johnson. Free cash flow hit $52.9 million for fiscal 2026, swinging from a loss the previous year.

Planet is projecting fiscal 2027 revenue between $415 million and $440 million, with first-quarter sales landing somewhere in the $87 million to $91 million range. The company’s adjusted EBITDA outlook remains cautious—anywhere from break-even to $10 million—as it continues to exclude certain costs and non-cash charges from that figure. Capital expenditures are set to reach $80 million to $95 million, signaling the company isn’t pulling back on its growth ambitions.

Just ahead of its earnings, Planet announced a collaboration with Nvidia to shift more image processing over to GPUs, targeting a jump from hours to seconds for converting raw pixels into actionable data. “AI could be transformative this year,” Planet CEO Will Marshall said. Jensen Huang, Nvidia’s chief, added, “intelligence must live wherever data is generated.” Business Wire

Planet isn’t the only one chasing this trend. Nvidia has pointed to clients like Aetherflux, Axiom Space, Kepler Communications, Sophia Space, and Starcloud, all tapping its space-computing platforms. It’s a signal the contest for in-orbit data processing is heating up fast. Reuters noted back in January that Google is looking to roll out a first Project Suncatcher prototype with Planet as soon as 2027, aiming to trial satellite-based AI computing.

Weaknesses remain. Gross margin in the fourth quarter dropped to 54%, down from 62% a year ago. Under standard accounting, net loss widened to $152.5 million, with a roughly $122.6 million revaluation loss linked to warrant liabilities as Planet’s share price climbed. The company also points out that some government customers can end contracts early, so not all backlog reliably converts to revenue.

Planet’s guidance points to sales outpacing profit growth for now. The company’s spending is ramping up, so the question is whether its AI initiatives and satellite services can eventually boost margins instead of just driving top-line gains.

Stock Market Today

  • Regentis Biomaterials Plans European Surgeon Training for GelrinC Implant
    June 9, 2026, 9:53 AM EDT. Regentis Biomaterials' shares edged down to $1.28 ahead of the New York open as the company outlined its European launch strategy for GelrinC, a knee cartilage repair hydrogel implant. The Israeli regenerative-medicine firm will begin surgeon training in Q3 at Humanitas Research Hospital in Milan, marking a key step between CE Mark regulatory clearance and commercial use in Europe. GelrinC's "off-the-shelf" design contrasts with custom-grown products, aiming to ease adoption. However, key uncertainties remain around FDA approval in the U.S., clinical trial outcomes, market acceptance, reimbursement, and competition from established implants by Smith+Nephew and Vericel. Regentis raised $10 million at its December 2025 IPO to fund pivotal U.S. trials and PMA submission. CEO Dr. Ehud Geller called training "critical" for physician adoption ahead of broader rollout.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
NAB share price falls 1.3% as oil shock and RBA risk hit National Australia Bank stock
Previous Story

NAB share price falls 1.3% as oil shock and RBA risk hit National Australia Bank stock

NIO Stock Price Rises as Shares Buck Tesla-Led Selloff After First-Ever Profit
Next Story

NIO Stock Price Rises as Shares Buck Tesla-Led Selloff After First-Ever Profit

Go toTop